Of the 61 patients with RET-mutant MTC previously treated with MKIs, 41 (67%) had M918T mutation, 14 (23%) had mutation in the cysteine rich domain, 2 (3%) had V804M/L mutations, and 4 (7%) had other RET mutations. Here, RET is linked to medullary thyroid gland carcinoma.